FEATURED COMPANIES
- AstraZeneca plc
- Boehringer-Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis AG
Anti-Asthmatics and COPD Drugs Global Market Opportunities and Strategies To 2030: COVID-19 Implications and Growth provides the strategists, marketers and senior management with the critical information they need to assess the global anti-asthmatics and COPD drugs market as it emerges from the COVID 19 shut down.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 12 geographies.
- Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market research findings.
- Benchmark performance against key competitors.
- Utilize the relationships between key data sets for superior strategizing.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.
Description:
Where is the largest and fastest growing market for anti-asthmatics and COPD drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The anti-asthmatics and COPD drugs market global report from the publisher answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography. It places the market within the context of the wider anti-asthmatics and COPD drugs market, and compares it with other markets.
The report covers the following chapters
- Executive Summary - The executive summary section of the report gives a brief overview and summary of the report.
- Report Structure - This section gives the structure of the report and the information covered in the various sections.
- Introduction - The introduction section of the report gives brief introduction about segmentation by geography, segmentation by drug class, segmentation by end-user, segmentation by distribution channel, segmentation by therapy, segmentation by route of administration, segmentation by age group, segmentation by prescription and segmentation by drug type.
- Market Characteristics - The market characteristics section of the report defines and explains the anti-asthmatics and COPD drugs market. This chapter also defines and describes products and related services covered in the report.
- Supply Chain -The supply chain section of the report defines and explains the key players in the anti-asthmatics and COPD drugs industry supply chain.
- Product Analysis -The product analysis section of the report describes the leading products in the market along with key features and differentiators for those products.
- Top 10 Leading Drugs Sales -The section describes list of top 10 drugs and their sales in the anti-asthmatics and COPD drug market in 2020. It briefs on the drug chemical composition, drug class and the manufacturers involved in manufacturing and selling of these leading drugs in the anti-asthmatics and COPD drugs market.
- Patent Analysis Of Leading Drugs -The section briefs on the patent analysis of the leading drugs in the anti-asthmatics and COPD drugs market, by focusing on the leading drugs’ patent expiry and emergence of the generic drugs in the market.
- Customer Information - This chapter covers recent customers’ trends/preferences in the global anti-asthmatics and COPD drugs market.
- Impact Of COVID-19 - This section describes the impact of COVID-19 on the anti-asthmatics and COPD drugs market.
- Regulatory Landscape - This section describes the regulatory bodies and regulations on the anti-asthmatics and COPD drugs market.
- Trends and Strategies - This chapter describes the major trends shaping the global anti-asthmatics and COPD drugs market. This section highlights likely future developments in the market and suggests approaches companies can take to exploit these opportunities.
- Asthma and COPD Prevalence Overview-This section describes about asthma and COPD and their prevalence in the major countries.
- Global Market Size and Growth - This section contains the global historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
- Regional Analysis - This section contains the historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values and growth and market share comparison by region.
- Segmentation - This section contains the market values (2015-2030) and analysis for different segments.
- Global Macro Comparison - The global anti-asthmatics and COPD drugs market comparison with macro-economic factors gives the anti-asthmatics and COPD drugs market size, percentage of GDP, and average anti-asthmatics and COPD drugs market expenditure.
- Regional Market Size and Growth - This section contains the region’s market size (2020), historic (2015-2020) and forecast (2020-2025), and (2025-2030) market values, and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region. The market overview sections of the report describe the current size of the market, background information, government initiatives, regulations, regulatory bodies, associations, corporate tax structure, investments, and major companies.
- Competitive Landscape - This section covers details on the competitive landscape of the global anti-asthmatics and COPD drugs market, estimated market shares and company profiles for the leading players.
- Key Mergers and Acquisitions - This chapter gives the information on recent mergers and acquisitions in the market covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
- Market Background - This section describes the respiratory diseases drugs market of which the anti-asthmatics and COPD drugs market is a segment. This chapter includes the respiratory diseases drugs market 2015-23 values, and regional analyses for the respiratory diseases drugs market.
- Market Opportunities and Strategies- This section includes market opportunities and strategies based on findings of the research. This section also gives information on growth opportunities across countries, segments and strategies to be followed in those markets. It gives an understanding of where there is significant business to be gained by competitors in the next five years.
- Conclusions and Recommendations - This section includes conclusions and recommendations based on findings of the research. This section also gives recommendations for anti-asthmatics and COPD drugs providers in terms of product offerings, geographic expansion, price offerings, marketing strategies and target groups.
- Appendix - This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.
Scope
Markets Covered:
- By Drug Class: Combination Drugs; Bronchodilators; Monoclonal Antibodies; Anti-Inflammatory Drugs
- By End User: Asthma Patients; COPD Patients
- By Distribution Channel: General Pharmacies; Hospital Pharmacies; Online Retailers
- By Age Group: Below 5 Years; 5 To 14 Years; 15-60 Years; Above 60 Years
- By Therapy: Preventive; Curative
- By Route Of Administration: Inhaled; Intravenous; Subcutaneous; Oral
- By Prescription: Prescription; OTC
- By Drug Type: Branded; Generics
Companies Mentioned:
GlaxoSmithKline plc.; AstraZeneca plc.; Boehringer-Ingelheim GmbH; F. Hoffmann-La Roche Ltd; Novartis AG
Metrics Covered:
Number of Enterprises; Number of Employees; Per Capita Expenditure
Countries:
China; India; Japan; Australia; Indonesia; South Korea; USA; Brazil; UK; Germany; France; Russia
Regions:
Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series:
Five years historic and ten years forecast.
Data:
Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; Anti-Asthmatics and COPD Drugs indicators comparison.
Data segmentations:
Country and regional historic and forecast data; market share of competitors; market segments.
Sourcing and Referencing:
Data and analysis throughout the report is sourced using end notes.
What is the estimated value of the Global Anti-Asthmatics and COPD Drugs Market?
What is the growth rate of the Global Anti-Asthmatics and COPD Drugs Market?
What is the forecasted size of the Global Anti-Asthmatics and COPD Drugs Market?
Who are the key companies in the Global Anti-Asthmatics and COPD Drugs Market?
FEATURED COMPANIES
- AstraZeneca plc
- Boehringer-Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis AG
FEATURED COMPANIES
- AstraZeneca plc
- Boehringer-Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline plc
- Novartis AG
The global anti-asthmatics and COPD drugs market reached a value of nearly $75,376.4 million in 2020, having increased at a compound annual growth rate (CAGR) of 12.7% since 2015. The market is expected to grow from $75,376.4 million in 2020 to $86,436.2 million in 2025 at a rate of 2.8%. The market is then expected to grow at a CAGR of 5.8% from 2025 and reach $114,413.5 million in 2030.
Growth factors in the historic period include increased prevalence of respiratory diseases, increased incidence of tobacco smoking, global warming, geriatric population, emerging markets, new methods for drug discovery, rise in healthcare expenditure. The market was restrained by expiration of patents, political uncertainties.
Going forward increased popularity of e-cigarettes/ vaping, rising obesity levels, technology, large pool of undiagnosed population, use of anti-asthmatics and COPD drugs to treat COVID-19 patients, increasing consumption of fats will drive the growth in the anti-asthmatics and COPD drugs market. Factors that could hinder the growth of the market in the future include side effects associated with respiratory drugs, reduction in free trade, stringent regulations.
The anti-asthmatics and COPD drugs market is segmented by type of drug class into combination drugs, bronchodilators, monoclonal antibodies, and anti-inflammatory drugs. The combination drugs market was the largest segment of the anti-asthmatics and COPD drugs market segmented by drug class, accounting for 37.4% of the total in 2020. Going forward, the monoclonal antibodies market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by drug class, at a CAGR of 6.3% during 2020-2025.
The anti-asthmatics and COPD drugs market is also segmented by type of end user into asthma patients, and COPD patients. The asthma patients end user market was the largest segment of the anti-asthmatics and COPD drugs market segmented by end user, accounting for 61.6% of the total in 2020. Going forward, the COPD patients end user market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by end user, at a CAGR of 3.1% during 2020-2025.
The anti-asthmatics and COPD drugs market is also segmented by distribution channel into general pharmacies, hospital pharmacies, and online retailers. The general pharmacies distribution channel market was the largest segment of the anti-asthmatics and COPD drugs market segmented by distribution channel, accounting for 65.3% of the total in 2020. Going forward, the online retailers distribution channel market segment is expected to be the fastest growing segment in the anti-asthmatics and COPD drugs market segmented by distribution channel, at a CAGR of 8.0% during 2020-2025.
The anti-asthmatics and COPD drugs market is also segmented by age group into below 5 years, 5 to 14 years, 15-69 years, and 70+ years. The 15-69 Years age group was the largest segment of the anti-asthmatics and COPD drugs market by age group, accounting for $37,950.2 million or 50.3% of the total market in 2020.
The anti-asthmatics and COPD drugs market is also segmented by therapy into preventive, and curative. The preventive was the largest segment of the anti-asthmatics and COPD drugs market by therapy, accounting for $40,897.4 million or 54.3% of the total market in 2020.
The anti-asthmatics and COPD drugs market is also segmented by route of administration into inhaled, intravenous and subcutaneous, and oral. The inhaled route of administration was the largest segment of the anti-asthmatics and COPD drugs market by route of administration, accounting for $55,104.4 million or 73.1% of the total market in 2020.
The anti-asthmatics and COPD drugs market is also segmented by prescription into prescription, and OTC. The prescription was the largest segment of the anti-asthmatics and COPD drugs market by prescription, accounting for $70,421.1 million or 93.4% of the total market in 2020.
The anti-asthmatics and COPD drugs market is also segmented by drug type into branded, and generics. The branded was the largest segment of the anti-asthmatics and COPD drugs market by drug type, accounting for $72,029.6 million or 95.6% of the total market in 2019.
North America was the largest region in the anti-asthmatics and COPD drugs market, accounting for 47.1% of the total in 2020. It was followed by the Asia-Pacific, Western Europe and then the other regions. Going forward, the fastest-growing regions in the anti-asthmatics and COPD drugs market will be Asia-Pacific and Middle East where growth will be at CAGRs of 6.6% and 4.1% respectively during 2020-2025. These will be followed by Africa and North America, where the markets are expected to register CAGRs of 2.9% and 1.8% respectively during 2020-2025.
The unprecedented outbreak of coronavirus has caused a surge in demand for essential pharmaceutical drugs, some bronchodilators, and medical devices including anti-asthmatics and COPD drugs. With governments across the world advising people to stay indoors and practice social distancing, to reduce the spread of the pandemic, individuals are hoarding these medications. This has created a sudden rise in demand for anti-asthmatics and COPD drugs. Anti-asthmatics and COPD drug companies should closely monitor the situation and increase supply of essential medicines and other medical devices for 3 to 6 months. Additionally, some anti-asthmatics and COPD drugs such as albuterol are being used in the treatment of COVID-19. In the wake of the pandemic, companies should focus on modifying their supply chain activities to maximize the output to keep up with the rising demand for these drugs.
The anti-asthmatics and COPD drugs market is slightly consolidated, with a small number of large players. The top ten competitors in the market made up to 33.96% of the total market in 2020. Major players in the market include GlaxoSmithKline plc., AstraZeneca plc., Boehringer-Ingelheim GmbH, F. Hoffmann-La Roche Ltd and Novartis AG.
The top growth potential in the anti-asthmatics and COPD drugs market by drug class will arise in monoclonal antibodies market, which will gain $5,055.64 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by end user will arise in the asthma patients market, which will gain $6,249.5 million of global annual sales by 2025. The top growth potential in the anti-asthmatics and COPD drugs market by distribution channel will arise in general pharmacies market, which will gain $4,863.6 million of global annual sales by 2025. The anti-asthmatics and COPD drugs market size will gain the most in the China’s anti-asthmatics and COPD drugs market at $4,273.5 million.
Market-trend-based strategies for the anti-asthmatics and COPD drugs include companies in the anti-asthmatics and COPD drugs market should invest in developing probiotic drugs for asthma to offer a full range of available treatments, developing anti-IL-5 drugs to expand their business portfolio, launching new innovative products to focus on establishing their market position and sustain their position among intense competition in the market, invest more in developing bioelectric medicines to improve asthma care, focus on increasing the number of collaborations to expand their business portfolio, explore opportunities in personalized medicine to counter the intense competition and provide customized treatment to individuals, invest in aerosol respiratory drugs for better efficacy, investing in biomarkers to produce more effective drugs in a smaller time frame, focus efforts on investing in generic drugs to counter the intense competition, developing combination drugs to offer better result, developing biologics to capitalize on the growing demand for biologics.
Player-adopted strategies in the anti-asthmatics and COPD drugs industry include GlaxoSmithKline’s growth strategy aims at investing more in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers, and consumers. Improving GSK’s pipeline of new medicines remains the first priority of the investment. AstraZeneca plc’s growth strategy aims at strengthening its anti-asthmatics and COPD drugs business through the expansion of its product portfolio. Boehringer Ingelheim’s growth strategy aims at expanding its anti-asthmatic drugs business through strategic investments focusing on expansion of its manufacturing operations. F. Hoffmann-La Roche Ltd.’s growth strategy aims at strengthening its position in the anti-asthmatics and COPD drug market by focusing on innovation in existing anti-asthmatics and COPD drugs. Novartis AG’s growth strategy aims at strengthening its position in the anti-asthmatics and COPD drugs market by focusing on the new drug development and continuous innovation.
To take advantage of the opportunities, the publisher recommends the anti-asthmatics and COPD drugs companies to focus on invest in probiotic drugs, focus on bioelectric medicines, leverage e-commerce to maximize reach and revenues, leverage online pharmacies, provide competitively priced offerings in low-income countries to reach new users, premium pricing for branded drugs, companies should focus on increasing awareness on asthma and COPD, leveraging medical advice that asthmatics should ensure they consistently stay up to date with preventative medication to protect against COVID-19, target geriatric populations
A selection of companies mentioned in this report includes:
- GlaxoSmithKline plc
- AstraZeneca plc
- Boehringer-Ingelheim GmbH
- F. Hoffmann-La Roche Ltd.
- Novartis AG
LOADING...